[Clinical study of cefotetan in complicated urinary tract infections].
Clinical effectiveness and safety of Cefotetan were evaluated in 28 patients with complicated urinary tract infections. The results were excellent in 12 patients (42.9%), moderate in 10 patients (35.7%) and poor in 6 patients (21.6%), and the effectiveness rate was 78.6%. Bacteriologically, 24 (75%) out of 32 strains were eradicated. Subjective side effects, nausea and abdominal discomfort, were observed in one patient. Abnormal laboratory findings were observed in 6 patients, eosinophilia in 3 patients and slight elevation of transaminase in 3 patients.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015313:Cefotetan; D002513:Cephamycins / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004802:Eosinophilia / Q000139:chemically induced; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000637:Transaminases / Q000097:blood; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D002513:Cephamycins; D015313:Cefotetan; D000637:Transaminases